NeoDynamics AB (publ) presents an abstract on preclinical results with its novel biopsy system NeoNavia at the St Gallen International Breast Cancer Conference 2021, which is held March 17-21, 2021 in Vienna.
In light of this event, NeoDynamics and Redeye are organizing a parallel digital presentation for the financial markets on Wednesday March 17 at 13.00 - 14.00 CET where CEO Anna Eriksrud and Dr Kai-Uwe Schässburger, Head of Clinical Development & Medical Affairs, will present the results and comment on the launch of the product. The presentation will be followed by a Q&A session led by Redeye’s analyst Oskar Bergman.
Please register to participate at Redeye at the following link: https://www.lyyti.in/Strategy_Update_NeoDynamics_9010
The presentation will be held in English.
The abstract will also be published in the scientific journal The Breast.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB. Phone +46 708 444 966, e-mail: email@example.com
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company has developed an innovative biopsy system, NeoNavia. The pulse biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated at leading clinics in UK, Germany and Sweden.
NeoNavia is the brand name for the entire pulse biopsy system intended to be used under ultrasound guidance. NeoNavia consists of a base unit, a handheld driver and three different types of biopsy needles. Each needle type is driven by a pulse technology enabling high precision and control when inserting and positioning the biopsy needle in a suspicious lesion. The system is designed to offer accurate lesion targeting and high tissue yield for correct diagnosis and individualized treatment.